Cytosorbents (CTSO) Enterprise Value (2016 - 2025)
Cytosorbents (CTSO) has disclosed Enterprise Value for 14 consecutive years, with -$7.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 15.94% year-over-year to -$7.5 million, compared with a TTM value of -$7.5 million through Sep 2025, down 15.94%, and an annual FY2024 reading of -$8.3 million, up 41.41% over the prior year.
- Enterprise Value was -$7.5 million for Q3 2025 at Cytosorbents, up from -$10.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.5 million in Q2 2024 and bottomed at -$68.5 million in Q1 2021.
- Average Enterprise Value over 5 years is -$25.2 million, with a median of -$14.1 million recorded in 2023.
- The sharpest move saw Enterprise Value plummeted 159.46% in 2021, then soared 63.06% in 2022.
- Year by year, Enterprise Value stood at -$52.1 million in 2021, then skyrocketed by 57.53% to -$22.1 million in 2022, then soared by 36.19% to -$14.1 million in 2023, then skyrocketed by 41.41% to -$8.3 million in 2024, then rose by 8.99% to -$7.5 million in 2025.
- Business Quant data shows Enterprise Value for CTSO at -$7.5 million in Q3 2025, -$10.2 million in Q2 2025, and -$11.6 million in Q1 2025.